Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H27FO5 |
Molecular Weight | 378.4345 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=WAIJIHDWAKJCBX-BULBTXNYSA-N
InChI=1S/C21H27FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h5,7,9,14-16,23,25,27H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
Molecular Formula | C21H27FO5 |
Molecular Weight | 378.4345 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Isoflupredone is a veterinary drug used in cows, pigs and horses for the treatment of wide range of conditions: ketosis, musculoskeletal disorders, hypersensitivity, infections, inflammatory diseases, etc. The drug belongs to the class of corticosteroids and exerts its therapeutic effect by binding to glucocorticoid and mineralocorticoid receptors of animals.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Animal Glucocorticoid receptor |
|||
Target ID: Animal Mineralocorticoid receptor |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | PREDEF Approved UseBovine Ketosis, Musculoskeletal Conditions, Allergic Reactions, Overwhelming Infections with Severe Toxicity, Shock, etc. Launch Date1959 |
|||
Palliative | PREDEF Approved UseBovine Ketosis, Musculoskeletal Conditions, Allergic Reactions, Overwhelming Infections with Severe Toxicity, Shock, etc. Launch Date1959 |
|||
Primary | PREDEF Approved UseBovine Ketosis, Musculoskeletal Conditions, Allergic Reactions, Overwhelming Infections with Severe Toxicity, Shock, etc. Launch Date1959 |
|||
Curative | PREDEF Approved UseBovine Ketosis, Musculoskeletal Conditions, Allergic Reactions, Overwhelming Infections with Severe Toxicity, Shock, etc. Launch Date1959 |
|||
Palliative | PREDEF Approved UseBovine Ketosis, Musculoskeletal Conditions, Allergic Reactions, Overwhelming Infections with Severe Toxicity, Shock, etc. Launch Date1959 |
|||
Palliative | PREDEF Approved UseBovine Ketosis, Musculoskeletal Conditions, Allergic Reactions, Overwhelming Infections with Severe Toxicity, Shock, etc. Launch Date1959 |
Sample Use Guides
The usual intramuscular dose for cattle is 10 to 20 mg, according to the size of the animal and severity of the condition. This dose may be repeated in 12 to 24 hours if indicated. The usual intramuscular dose for horses is 5 to 20 mg repeated as necessary. The usual intramuscular dose for swine is 5 mg for a 300 pound animal.
Route of Administration:
Intramuscular
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:46:22 GMT 2023
by
admin
on
Fri Dec 15 15:46:22 GMT 2023
|
Record UNII |
HYS0B45Z2S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 524.1484C
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
||
|
CFR |
21 CFR 524.1484B
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
206-422-3
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL1608183
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
m6490
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
12174
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
DB11522
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
338-95-4
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
100000082810
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
HYS0B45Z2S
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
SUB08318MIG
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
127516
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
Isoflupredone
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
4007
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
C77004
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
1546449
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | RxNorm | ||
|
C010958
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
HYS0B45Z2S
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY | |||
|
DTXSID10100933
Created by
admin on Fri Dec 15 15:46:22 GMT 2023 , Edited by admin on Fri Dec 15 15:46:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |